desipramine has been researched along with Anti-MuSK Myasthenia Gravis in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Pardey-Maldonado, B | 1 |
| John, E | 1 |
| Jimenez, V | 1 |
| Orozco, B | 1 |
| Baez, S | 1 |
| Lechin, ME | 1 |
1 trial available for desipramine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Enhancement of noradrenergic neural transmission: an effective therapy of myasthenia gravis: a report on 52 consecutive patients.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Ad | 2000 |